Nextech Invest is a venture capital and private equity firm specializing in early, mid-stage, late-stage, and emerging growth.
Business Model:
Revenue: $5.3M
Employees: 2-10
Address: Scheuchzerstrasse 35
City: Zurich
State: other
Zip: 8006
Country: CH
Nextech Invest is a venture capital and private equity firm specializing in early, mid-stage, late-stage, and emerging growth investments. The firm also invests in incorporation, spin-outs, reverse-take-over, and PIPE transactions. It only considers investments where evidence in preclinical animal models that a drug is efficacious is available or a device prototype fulfills the requirements. The firm seeks to invest in the field of information technology, biotechnology, and healthcare with a focus on oncology companies developing cancer drugs and diagnostics. It prefers to invest in life science and enabling technologies with a focus on interdisciplinary technical and scientific projects, therapies, diagnostics, medical technologies, and services. The firm seeks to invest in companies based in Africa, the Middle East, Asia, North America, and Europe including Switzerland, Germany, and neighboring regions. It also considers co-investments in the rest of Europe. The firm seeks to invest between CHF 1 million ($0.93 million) and CHF 5 million ($4.7 million) per financing round. It seeks a Board position in the portfolio companies. The firm seeks to exit its investments within three years via trade sale. Nextech Invest Ltd. was founded in 1998 and is based in Zurich, Switzerland.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
9/2017 | Autolus | Series C | 80M |
9/2017 | ImaginAb | Venture Round | 0 |
3/2020 | Circle Pharma | Series B | 0 |
11/2019 | PMV Pharmaceuticals | Series C | 0 |
3/2020 | Silverback Therapeutics | Series B | 0 |
9/2016 | Peloton Therapeutics | Series D | 0 |
1/2021 | Scorpion Therapeutics | Series B | 162M |
4/2021 | Theseus Pharmaceuticals | Series B | 0 |
12/2019 | Kinnate Biopharma | Series B | 74.5M |
1/2022 | Alterome Therapeutics | Series A | 0 |
11/2014 | Blueprint Medicines | Series C | 50M |
3/2021 | Tyra Biosciences | Series B | 106M |
4/2021 | Boundless Bio | Series B | 105M |
4/2018 | Revolution Medicines | Series B | 56M |
9/2021 | Hexagon Bio | Series B | 61M |
4/2019 | Vividion Therapeutics | Series B | 82M |
4/2020 | MOMA Therapeutics | Series A | 86M |
10/2018 | Turning Point Therapeutics | Equity | 80M |
5/2023 | Boundless Bio | Series C | 0 |
12/2022 | Alpha9 Theranostics | Series B | 0 |
11/2022 | Alterome Therapeutics | Series A | 0 |
10/2022 | Hexagon Bio | Series B | 0 |
8/2022 | Idrx | Series A | 0 |
10/2021 | Exo Therapeutics | Series B | 0 |
3/2023 | Flare Therapeutics | Series B | 0 |
5/2011 | TetraLogic Pharmaceuticals | Series C | 6M |
7/2005 | Ganymed Pharmaceuticals | Series B | 14.4M |
5/2014 | ImaginAb | Series B | 21M |
12/2017 | Neon Therapeutics | Series B | 36M |
6/2020 | C4 Therapeutics | Series B | 150M |
4/2011 | TRACON Pharmaceuticals | Series A | 14M |
7/2019 | Revolution Medicines | Series C | 100M |
3/2018 | IDEAYA Biosciences | Series B | 0 |
7/2007 | Agensys | Series D | 41.3M |
3/2015 | Kura Oncology | Private Equity Round | 60M |
6/2002 | Ganymed Pharmaceuticals | Series A | 8.3M |
9/2008 | Telormedix | Series A | 0 |
4/2015 | Jounce Therapeutics | Series B | 0 |
1/2021 | EQRx | Series B | 500M |
8/2016 | Cleave Therapeutics | Series B | 0 |
2/2021 | Vividion Therapeutics | Series C | 135M |
10/2020 | A2 Biotherapeutics | Series B | 71.5M |
9/2014 | TRACON Pharmaceuticals | Series B | 0 |
1/2022 | AmbAgon Therapeutics | Series A | 0 |
12/2019 | Black Diamond Therapeutics | Series C | 0 |
3/2023 | CARGO Therapeutics | Series A | 0 |
1/2019 | Black Diamond Therapeutics | Series B | 85M |
1/2017 | Neon Therapeutics | Series B | 70M |
1/2014 | Blueprint Medicines | Series B | 25M |
8/2020 | PMV Pharmaceuticals | Series D | 70M |
5/2021 | Flare Therapeutics | Series A | 82M |
4/2009 | Sunesis Pharmaceuticals | Post-IPO Equity | 0 |
12/2020 | Cullinan Oncology | Series C | 131.2M |
1/2021 | IconOVir Bio | Series A | 0 |
7/2019 | Kronos Bio | Series A | 105M |
4/2012 | MolecularMD | Series B | 6M |
6/2023 | K36 Therapeutics | Series B | 0 |
6/2023 | ORIC Pharmaceuticals | Post-IPO Equity | 0 |
6/2023 | Isotopen Technologien München | Private Equity Round | 0 |
11/2019 | A2 Biotherapeutics | Series A | 57M |
2/2019 | Peloton Therapeutics | Series E | 0 |
1/2020 | EQRx | Series A | 200M |
9/2020 | Silverback Therapeutics | Series C | 85M |
6/2021 | Circle Pharma | Series C | 0 |
8/2021 | Atavistik Bio | Series A | 60M |
5/2022 | MOMA Therapeutics | Series B | 0 |
4/2019 | Arrakis Therapeutics | Series B | 75M |
4/2018 | Arvinas | Series C | 55M |
8/2020 | Kronos Bio | Private Equity Round | 155M |
8/2020 | Kinnate Biopharma | Series C | 98M |
6/2023 | K36 Therapeutics | Series B | 0 |
6/2023 | ORIC Pharmaceuticals | Post-IPO Equity | 0 |
6/2023 | Isotopen Technologien München | Private Equity Round | 0 |
5/2023 | Boundless Bio | Series C | 0 |
3/2023 | Flare Therapeutics | Series B | 0 |
3/2023 | CARGO Therapeutics | Series A | 0 |
12/2022 | Alpha9 Theranostics | Series B | 0 |
11/2022 | Alterome Therapeutics | Series A | 0 |
10/2022 | Hexagon Bio | Series B | 0 |
8/2022 | Idrx | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|